1.Modulation of gene expression dynamics by co-transcriptional histone methylations.
Hyeonju WOO ; So Dam HA ; Sung Bae LEE ; Stephen BURATOWSKI ; TaeSoo KIM
Experimental & Molecular Medicine 2017;49(4):e326-
Co-transcriptional methylations of histone H3 at lysines 4 and 36, highly conserved methyl marks from yeast to humans, have profound roles in regulation of histone acetylation. These modifications function to recruit and/or activate distinct histone acetyltransferases (HATs) or histone deacetylases (HDACs). Whereas H3K4me3 increases acetylation at promoters via multiple HATs, H3K4me2 targets Set3 HDAC to deacetylate histones in 5' transcribed regions. In 3' regions of genes, H3K36me2/3 facilitates deacetylation by Rpd3S HDAC and slows elongation. Despite their important functions in deacetylation, no strong effects on global gene expression have been seen under optimized or laboratory growth conditions. Instead, H3K4me2-Set3 HDAC and Set2-Rpd3S pathways primarily delay the kinetics of messenger RNA (mRNA) and long noncoding RNA (lncRNA) induction upon environmental changes. A majority of mRNA genes regulated by these pathways have an overlapping lncRNA transcription either from an upstream or an antisense promoter. Surprisingly, the distance between mRNA and lncRNA promoters seems to specify the repressive effects of the two pathways. Given that co-transcriptional methylations and acetylation have been linked to many cancers, studying their functions in a dynamic condition or during cancer progression will be much more important and help identify novel genes associated with cancers.
Acetylation
;
Gene Expression*
;
Histone Acetyltransferases
;
Histone Deacetylases
;
Histones*
;
Humans
;
Kinetics
;
Methylation*
;
RNA, Long Noncoding
;
RNA, Messenger
;
Yeasts
2.Clinical and Laboratory Factors Associated with Symptom Development in Asymptomatic COVID-19 Patients at the Time of Diagnosis
Hong Sang OH ; Joon Ho KIM ; Myoung Lyeol WOO ; Ji-Yeon KIM ; Chul Hee PARK ; Hyejin WON ; Seungkwan LIM ; Hyeonju JEONG ; Sin Young HAM ; Eun Jin KIM ; Seungsoo SHEEN ; Yu Min KANG ; Doran YOON ; Seung Youp LEE ; Kyoung-Ho SONG
Infection and Chemotherapy 2021;53(4):786-791
In preparation for the surge of coronavirus disease 2019 (COVID-19), it is crucial to allocate medical resources efficiently for distinguishing people who remain asymptomatic until the end of the disease. Between January 27, 2020, and April 21, 2020, 517 COVID-19 cases from 13 healthcare facilities in Gyeonggi province, Korea, were identified out of which the epidemiologic and clinical information of 66 asymptomatic patients at the time of diagnosis were analyzed retrospectively. An exposure-diagnosis interval within 7 days and abnormal aspartate aminotransferase levels were identified as characteristic symptom development in asymptomatic COVID-19 patients. If asymptomatic patients without these characteristics at the time of diagnosis could be differentiated early, more medical resources could be secured for mild or moderate cases in this COVID-19 surge.